Liposomal amphotericin B for mold infections after liver transplant
Part of Immune system & allergy, Infections clinical trials.
This trial tests the safety and effectiveness of a medicine called liposomal amphotericin B for treating serious mold infections in liver transplant recipients. It compares this medicine to another antifungal called voriconazole, and may help find the best way to treat these infections after a liver transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 12 years old or older
- You have received a liver transplant
- You have a confirmed or likely serious mold infection (invasive mold disease)
- You have already received at least one dose of either liposomal amphotericin B or voriconazole
- You have not been treated with amphotericin B for more than 5 days in the past for a mold infection
- You are not pregnant or breastfeeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well a medicine called liposomal amphotericin B works for treating serious fungal infections in people who have had a solid organ transplant. It may help doctors understand the best way to use this medicine for patients like you.
This trial looks at how a specific antifungal medicine, called liposomal amphotericin B, given over a longer period, helps prevent serious fungal infections in people undergoing treatment for cancer or receiving a stem cell transplant. It may be an option if you are at high risk for these infections.
This study tests a new antifungal drug (EL219) compared to two standard treatments (liposomal amphotericin B or voriconazole) for people with weakened immune systems who have a suspected or confirmed mold infection. The goal is to see if the new drug works as well or better at treating the infection.
This trial tests a medication called liposomal amphotericin B for people with a serious fungal infection (aspergillosis) who also have liver problems. The goal is to see if this treatment is safe and effective for them.
This study follows children and teens with blood cancers who got a fungal infection while on preventive antifungal medicine. It looks at how well liposomal amphotericin B (AmBisome) works and how safe it is for them.
This trial tests amphotericin B (an antifungal medication) in patients with blood cancers who develop a fungal infection despite already taking antifungal preventive medicine. The study aims to see if this medication can treat these hard-to-treat infections.
Hear when a new Invasive Mold Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.